Literature DB >> 17915074

Why buprenorphine is so successful in treating opiate addiction in France.

M Fatseas1, Marc Auriacombe.   

Abstract

In France, all registered medical doctors have been allowed to prescribe buprenorphine without any special education or licensing since 1995. This has led to a rapidly increasing number of opiate-dependent users under buprenorphine treatment in primary care. French physician compensation mechanisms, pharmacy services, and medical insurance funding all have contributed to minimizing barriers to buprenorphine treatment. Approximately 20% of all physicians in France are prescribing buprenorphine to treat more than one half of the estimated 180,000 problem heroin users. Intravenous diversion of buprenorphine may occur in up to 20% of buprenorphine patients and has led to relatively rare overdoses in combination with sedatives, whereas total opiate overdose deaths have declined substantially. In France, buprenorphine maintenance treatment for problem opiate users was feasible and safe through office-based prescriptions in a relaxed regulatory environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915074     DOI: 10.1007/s11920-007-0046-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  33 in total

1.  [Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians].

Authors:  M De Ducla; A Gagnon; A Mucchielli; S Robinet; A Vellay
Journal:  Ann Med Interne (Paris)       Date:  2000-04

2.  [The financial impact of maintenance treatment in heroin addictive behavior: the case of Subutex].

Authors:  P Kopp; C Rumeau-Pichon; C Le Pen
Journal:  Rev Epidemiol Sante Publique       Date:  2000-06       Impact factor: 1.019

3.  Six deaths linked to misuse of buprenorphine-benzodiazepine combinations.

Authors:  M Reynaud; A Tracqui; G Petit; D Potard; P Courty
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

4.  Unsafe injecting practices among attendees of syringe exchange programmes in France.

Authors:  M Valenciano; J Emmanuelli; F Lert
Journal:  Addiction       Date:  2001-04       Impact factor: 6.526

5.  French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse?

Authors:  Isabelle Feroni; Patrick Peretti-Watel; Alain Paraponaris; Alain Masut; Eleonore Ronfle; Jean-Claude Mabriez; Yolande Obadia
Journal:  J Addict Dis       Date:  2005

6.  [Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997].

Authors:  X Thirion; J Micallef; F Guet; J C Delarozière; J Arditti; A Huntsman; J L Sanmarco; G Lagier
Journal:  Therapie       Date:  1999 Mar-Apr       Impact factor: 2.070

7.  Buprenorphine prescription by general practitioners in a French region.

Authors:  X Thirion; V Lapierre; J Micallef; E Ronflé; A Masut; V Pradel; C Coudert; J C Mabriez; J L Sanmarco
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

8.  [Effect of maintenance treatments on social life. A study with general practitioners].

Authors:  Sibel Bilal; Juan Menares; Patrick De La Selle; Abdalla Toufik; Yohann Perdrieux
Journal:  Ann Med Interne (Paris)       Date:  2003-11

9.  Homelessness and high-dosage buprenorphine misuse.

Authors:  T Blanchon; A Boissonnas; I Vareseon; G Vidal-Trecan
Journal:  Subst Use Misuse       Date:  2003 Feb-May       Impact factor: 2.164

10.  Six deaths linked to concomitant use of buprenorphine and benzodiazepines.

Authors:  M Reynaud; G Petit; D Potard; P Courty
Journal:  Addiction       Date:  1998-09       Impact factor: 6.526

View more
  34 in total

Review 1.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

2.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

3.  An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders.

Authors:  M Eugenia Socías; Keith Ahamad
Journal:  CMAJ       Date:  2016-11-07       Impact factor: 8.262

4.  Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

Authors:  Sarah A Weicker; Kanna Hayashi; Cameron Grant; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2019-10-25       Impact factor: 4.492

5.  States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Jennifer R Havens; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

6.  Treating Addictions: Harm Reduction in Clinical Care and Prevention.

Authors:  Ernest Drucker; Kenneth Anderson; Robert Haemmig; Robert Heimer; Dan Small; Alex Walley; Evan Wood; Ingrid van Beek
Journal:  J Bioeth Inq       Date:  2016-04-26       Impact factor: 1.352

7.  A Public Health Strategy for the Opioid Crisis.

Authors:  Brendan Saloner; Emma E McGinty; Leo Beletsky; Ricky Bluthenthal; Chris Beyrer; Michael Botticelli; Susan G Sherman
Journal:  Public Health Rep       Date:  2018 Nov/Dec       Impact factor: 2.792

8.  Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study.

Authors:  Julie Dupouy; Aurore Palmaro; Mélina Fatséas; Marc Auriacombe; Joëlle Micallef; Stéphane Oustric; Maryse Lapeyre-Mestre
Journal:  Ann Fam Med       Date:  2017-07       Impact factor: 5.166

Review 9.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

10.  Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002.

Authors:  Estelle Lavie; Mélina Fatséas; Jean-Pierre Daulouède; Cécile Denis; Jacques Dubernet; Laurent Cattan; Marc Auriacombe
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.